Recurrent Ovarian High Grade Serous Adenocarcinoma

7 clinical trials · Condition

Record	Firm	Date
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (NCT06393751)	National Cancer Institute (NCI)	2025-10-31
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (NCT05950464)	National Cancer Institute (NCI)	2023-12-18
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT05920798)	Mayo Clinic	2023-09-28
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (NCT05295589)	National Cancer Institute (NCI)	2022-06-30
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (NCT05039801)	M.D. Anderson Cancer Center	2021-09-30
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer (NCT04633239)	National Cancer Institute (NCI)	2021-07-02
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800)	National Cancer Institute (NCI)	2021-06-10

Every clearance here is in the API, with alerts when new ones post.